| Bioactivity | BChE-IN-13 (Compound 17c) is an orally active, potent and selective Butyrylcholinesterase (BChE) inhibitor with IC50s of 0.22 and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 can improve memory and cognitive impairments, and be used in Alzheimer’s disease (AD) research[1]. |
| Target | IC50: 0.22 μM (eqBChE) 0.016 μM (hBChE) |
| Invitro | BChE-IN-13 (5-100 μM; 24 h) shows weak toxicity to SH-SY5Y, PC-12 and HT-22, and shows high mortality to BV2 cells[1].BChE-IN-13 shows excellent blood brain barrier permeation using a parallel artificial membrane permeability assay experiment (PAMPA)[1]. Cell Cytotoxicity Assay[1] Cell Line: |
| In Vivo | BChE-IN-13 (oral gavage; 15 mg/kg; once daily; 6 d) shows the improvement in memory and cognitive function in Aβ1-42 induced AD-like disorder mice[1]. Animal Model: |
| Name | BChE-IN-13 |
| CAS | 2700896-73-5 |
| Formula | C24H28N2O |
| Molar Mass | 360.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xin Lu, et al. Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease. |
BChE-IN-13
CAS: 2700896-73-5 F: C24H28N2O W: 360.49
BChE-IN-13 (Compound 17c) is an orally active, potent and selective Butyrylcholinesterase (BChE) inhibitor with IC50s of
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.